CORPORATE
Glenmark arm IGI licenses Abbvie to develop and make cancer treatment drug
- IBJ Bureau
- Jul 11, 2025
Glenmark Pharmaceuticals’ innovation arm Ichnos Glenmark Innovation (IGI) and AbbVie have signed an exclusive licensing agreement for IGI’s cancer treatment, adding to the US firm’s oncology portfolio.
Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialise IGI’s ISB 2001 in North America, Europe, Japan and Greater China.
ISB 2001 is currently in phase-I clinical trial in patients with relapsed or refractory multiple myeloma, a type of cancer that develops in white blood cells.
AbbVie has a pipeline of more than 20 investigational assets designed to tackle difficult-to-treat cancers, according to the company website.
IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, subject to regulatory approvals, according to the agreement.
“AbbVie’s reach in major markets, combined with Glenmark’s commercial strength in emerging markets, creates complementary access pathways for ISB 2001, a tri-specific T-cell engager with promising potential in multiple nyeloma,” IGI CEO, President and Executive Director Cyril Konto has said.
Report By
View Reporter News